Active Ingredient History

  • Now
Cevimeline is a cholinergic agonist, which binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands and increase tone of the smooth muscle in the gastrointestinal and urinary tracts. Cevimeline is indicated for the treatment of symptoms of dry mouth in patients with Sjögren’s Syndrome. Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping. Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances. Drugs with para-sympathomimetic effects administered concurrently with cevimeline can be expected to have additive effects. Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly.   NCATS

More Chemistry

Drug Pricing (per unit)

United States

$0.1606 - $7.1592
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

2-methyspiro(1,3-oxathiolane-5,3)quinuclidine | af102b | af 102b | af-102b | af 102b, (cis-(+))-isomer | af 102b, (trans)-isomer | cevimelina | cevimeline | cevimeline hcl | cevimeline hydrochloride | cevimeline hydrochloride hemihydrate | cevimeline hydrochloride hydrate | cevimelinum | evoxac | fks 508 | fks-508 | snd-5008 | sni 2011 | sni-2011 | snk-508


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue